2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
6
Brain Neoplasms
3
Neoplasms
2
Lung Neoplasms
2
Thrombophilia
1
Stomatitis
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Periodontitis
1
Patient Satisfaction
1
Neoplasms, Plasma Cell
1
Motor Activity
1
Liver Neoplasms
1
Liver Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Febrile Neutropenia
1
EGFR-Mutant Lung Cancer
1
Deglutition Disorders
1
Communication Disorders
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Diseases
1
Blood Coagulation Disorders
1
Advanced Breast Cancer
1
Interventions
Gemcitabine
15
130-nm albumin-bound paclitaxel
10
Albumin-Bound Paclitaxel
7
Oxaliplatin
5
Paclitaxel
4
Leucovorin
4
Fluorouracil
4
Carboplatin
4
Cisplatin
3
Cetuximab
3
Bevacizumab
3
pembrolizumab
2
napabucasin
2
Pemetrexed
2
PEGPH20
2
MK-4721
2
Irinotecan
2
tremelimumab
1
selinexor
1
relacorilant
1
ponatinib
1
neratinib
1
irinotecan sucrosofate
1
folfirinox
1
ensituximab
1
durvalumab
1
contrast agent BR1
1
cobimetinib
1
ceritinib
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Pancreatic Ductal
×
Lead
×
Clear all
NCT01808638
2016-03-11
Atu027-I-02
Silence Therapeutics GmbH
Phase 1/2
Completed
29 enrolled